Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Reuters Citing Conf. Call
- 48-week data show a 64% decrease from baseline in proteinuria in IgA nephropathy, 82% decrease from baseline in proteinuria i...
UBS analyst Colin Bristow maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and lowers the price target from $553 to...
FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescr...
Risk appetite cooled on Tuesday as investors interpreted the latest batch of corporate earnings as solid but not spectacular, o...
RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Sector Perform and lowers the price...
Barclays analyst Gena Wang maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Equal-Weight and raises the price target fr...
Stifel analyst Paul Matteis maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Hold and lowers the price target from $455...
Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2025 sales outlook from $11.850 billion-$12.000 billion to $11.900 billion-$12.00...
